1. Abd El Rahman MY, Abdul-Khaliq H, Vogel M, Alexi-
Meskishvili V, Gutberlet M, Lange PE. Relation between
right ventricular enlargement, QRS duration, and right
ventricular function in patients with tetralogy of Fallot
and pulmonary regurgitation after surgical repair. Heart
2000;84:416-420.
2. Adamson L, Vohra, HA, Haw MP. Does pulmonary
valve replacement post repair of tetralogy of Fallot
improve right ventricular function? Interactive
CardioVascular and Thoracic Surgery,
September 1, 2009; 9: 520 – 527.
3. Asoh K, Walsh M, Hickey E, Nagiub M, Chaturvedi R,
Lee KJ, Benson LN.Percutaneous pulmonary valve
implantation within bioprosthetic valves. Eur Heart J.
2010;31:1404-1409.
4. Berul CI, Hill SL, Geggel RL, Hijazi ZM, Marx GR,
Rhodes J, Walsh KA, Fulton DR. Electrocardiographic
markers of late sudden death risk in postoperative
tetralogy of Fallot children. J Cardiovasc Electrophysiol
1997;8:1349-1356.
5. Dittrich S, Gloeckler M, Arnold R, Sarai K, Siepe M,
Beyersdorf F, Schlensak C. Hybrid pulmonary valve
implantation: injection of a self-expanding tissue valve
through the main pulmonary artery. Ann Thorac Surg.
2008;85:632-634.
6. Fiore AC, Rodefeld M, Turrentine M, Vijay P, Reynolds
T, Standeven J, Hill K, Bost J, Carpenter D, Tobin C,
Brown JW. Pulmonary valve replacement: a comparison
of three biological valves. Ann Thorac Surg
2008;85:1712-1718.
7. Gatzoulis MA, Balaji S, Webber SA, Siu SC, Hokanson
JS, Poile C, Rosenthal M, Nakazawa M, Moller JH,
Gillette PC, Webb GD, Redington AN. Risk factors for
arrhythmia and sudden cardiac death late after repair of
tetralogy of Fallot: a multicentre study. Lancet
2000;356:975-981.
İstanbul Tıp Fakültesi Dergisi Cilt / Volume: 74 • Sayı / Number: 3 • Yıl/Year: 2011
53
Fallot tetralojisi
İstanbul Tıp Fakültesi Dergisi Cilt / Volume: 74 • Sayı / Number: 3 • Yıl/Year: 2011
8. Gengsakul A, Harris L, Bradley TJ, Webb GD,
Williams WG, Siu SC, Merchant N, McCrindle BW.
The impact of pulmonary valve replacement after
tetralogy of Fallot repair: a matched comparison. Eur J
Cardiothorac Surg 2007;32:462-468.
9. Hoelzer D, Thiel E, Löffler H, Büchner T, Ganser A,
Heil G, Koch P, Freund M, Diedrich H, Rühl H.
Prognostic factors in a multicenter study for treatment
of acute lymphoblastic leukemia in adults. Blood.
1988;71 :123-131.
10. Hoelzer DR. Therapy of the newly diagnosed adult with
acute lymphoblastic leukemia. Hematol Oncol Clin
North Am. 1993;7 :139–160.
11. Hussein KK, Dahlberg S, Head D, Waddell CC, Dabich
L, Weick JK, Morrison F, Saiki JH, Metz E, Rivkin SE.
Treatment of acute lymphoblastic leukemia in adults
with intensive induction, consolidation, and
maintenance chemotherapy. Blood. 1989;73 :57–63.
12. Kantarjian H, Thomas D, O'Brien S, Cortes J, Giles F,
Jeha S, Bueso-Ramos CE, Pierce S, Shan J, Koller C,
Beran M, Keating M, Freireich EJ. Long-term followup
results of hyperfractioned cyclophosphamide,
vincristine, doxorubicin, and dexamethasone (Hyper-
CVAD), a dose-intensiveregimen, in adult acute
lymphoblastic leukemia. Cancer 2004;101 :2788-2801.
13. Kantarjian HM, Walters RS, Keating MJ, Smith TL,
O'Brien S, Estey EH, Huh YO, Spinolo J, Dicke K,
Barlogie B. Results of the vincristine, doxorubicin, and
dexamethasone regimen in adults with standard- and
high-risk acute lymphocytic leukemia. J Clin Oncol.
1990;8 :994–1004.
14 .Larson RA, Dodge RK, Burns CP, Lee EJ, Stone RM,
Schulman P, Duggan D, Davey FR, Sobol RE, Frankel
SR. A five-drug remission induction regimen with
intensive consolidation for adults with acute
lymphoblastic leukemia: Cancer and Leukemia Group
B Study 8811. Blood. 1995;85:2025-2037.
15. Larson RA. Recent clinical trials in acute lymphoblastic
leukeima by the Cancer and Leukemia Group B.
Hematol Oncol Clin North Am. 2000;14 :1367–1379.
16. Le QH, Thomas X, Ecochard R, Iwaz J, Lhéritier V,
Michallet M, Fiere D. Initial and late prognostic factors
to predict survival in adult acute lymphoblastic
leukaemia. Eur J Haematol. 2006;77 :471-479.
17. Linker CA, Levitt LJ, O’Donnell M, Forman SJ, Ries
CA. Treatment of adult acute lymphoblastic leukemia
with intensive cyclical chemotherapy: A follow-up
report. Blood. 1991;78 :2814–2822.
18. Moorman AV, Harrison CJ, Buck GA, Richards SM,
Secker-Walker LM, Martineau M, Vance GH, Cherry
AM,Higgins RR, Fielding AK, Foroni L, Paietta E,
Tallman MS, Litzow MR, Wiernik PH, Rowe JM,
Goldstone AH, Dewald GW; Adult Leukaemia
Working Party, Medical Research Council/National
Cancer Research Institute. Karyotype is an independent
prognostic factor in adult acute lymphoblastic leukemia
(ALL): analysis of cytogenetic data from patients
treated on the Medical Research Council (MRC)
UKALL-XII/Eastern Cooperative Oncology Group
(ECOG)2993 trial. Blood. 2007;109 :3189-3197.
19. Nowak-Gottl U, Ahlke E, Fleischhack G, Schwabe D,
Schobess R, Schumann C, Junker R. Thromboembolic
events in children with acute lymphoblastic leukemia
(BFM protocols): prednisone versus dexamethasone
administration. Blood. 2003;101 :2529–2533.
20. Pullarkat V, Slovak MI, Kopecky KJ, Forman SJ and
Appelbaum FR. Impact of cytogenetics on the outcome
of adult acute lymphoblastic leukemia: results of
Southwest Oncology Group 9400 study. Blood.
2008;111 :2563-2572.
21. Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik
PH, Richards SM, Lazarus HM, Franklin IM, Litzow
MR, Ciobanu N, Prentice HG, Durrant J, Tallman MS,
Goldstone AH; ECOG; MRC/NCRI Adult Leukemia
Working Party. Induction therapy for adults with acute
lymphoblastic leukemia: results of more than 1500
patients from the international ALL trial: MRC
UKALL XII/ECOG E2993. Blood. 2005;106 :3760-
3767.
22. Thomas X, Le QH. Prognostic factors in adult acute
lymphoblastic leukemia. Hematology. 2003;8 :233-
242.
23. Thomas X, Danaila C, Le QH, Sebban C, Troncy J,
Charrin C, Liheritier V, Michallet M, Magaud JP, Fiere
D. Long-term follow-up of patients with newly
diagnosed adult acute lymphoblastic leukemia: A single
institution experience of 378 consecutive patients over
a 21-year period. Leukemia. 2001;15 :1811-1822.
24. Taylor PRA, Reid MM, Brown N, Hamilton PJ, Proctor
SJ. Acute lymphoblastic leukemia in patients aged 60
years an over: a population-based study if incidence
and outcome. Blood. 1992;80 :1813-1817.
25. Xu W, Li JY, Qian SX, Wu HX, Lu H, Chen LJ, Zhang
SJ, Lu RL, Sheng RL. Outcome of treatment with
Hyper-CVAD regimen in Chinese patients with acute
lymphocytic leukemia. Leuk Res. 2008;32 :930-935.
26. Verma A, Stock W. Management of adult acute
lymphoblastic leukemia: moving toward a risk-adapted
approach. Curr Opin Oncol. 2001;13 :14-20.
Thank you for copying data from http://www.arastirmax.com
